Natera is deepening its footprint in precision oncology with the acquisition of Foresight Diagnostics in an all-stock deal worth up to $450 million. This move brings together Natera’s personalised MRD platform and Foresight’s ultra-sensitive liquid biopsy tech, capable of detecting cancer DNA at 0.1 parts per million, to enhance detection and monitoring in cancers like lymphoma. Natera’s CEO Steve Chapman said this combination “reinforces our position at the forefront of precision oncology”.

In other precision diagnostics news, Quest Diagnostics is also advancing personalised care with the launch of a pharmacogenomics (PGx) testing service that sequences 17 genes to help predict drug response across cardiology, psychiatry, oncology, and more. Through a partnership with InformedDNA’s Coriell Life Sciences unit, Quest Diagnostics will deliver decision-support tools to help providers personalise treatments and avoid adverse reactions.

Meanwhile, Samsung’s healthcare group is teaming up with GRAIL to introduce the Galleri multi-cancer early detection blood test to Asian markets. Backed by a $110 million investment, the partnership will support rollout in South Korea, while exploring AI-integrated screening platforms.

Together, these moves reflect the accelerating shift toward ultra-precise diagnostics, genomic-guided therapies, and data-driven early detection, core pillars of the Precision & Molecular Diagnostics Zone at Med4Nexus.